Breast Cancer Coverage from Every Angle


AACR 2024: New-Generation PARP Inhibitor Under Study in HER2-Negative Breast Cancer
ASBrS 2024: How Will the Decline of Surgical Reimbursements Impact Breast Cancer Care?
AACR 2024: Novel Compounds May Target MIEN1 Pathway to Treat Breast Cancer
Retrospective Study Offers Insight Into Possible Overuse of Axillary Surgery
AACR 2024: DARPP-32 Protein and Progression of Breast Cancer
AACR 2024: Study Finds Potentially Targetable Mechanistic Pathway in Breast Cancer
AACR 2024: Classifying Patients With Triple-Negative Breast Cancer Based on Cellular Biomarkers
SSO 2024: De-escalation of Locoregional Therapy for Ductal Carcinoma in Situ
SSO 2024: Changes in Biomarker Profiles After Neoadjuvant Therapy for Breast Cancer
Can MRI Surveillance Reduce Breast Cancer Mortality in Women With BRCA1/2 Variations?
Identifying Residual Nodal Disease After Neoadjuvant Therapy for Breast Cancer: Focus on Clipped Axillary Node
EBCC 2024: Atezolizumab Plus Adjuvant Chemotherapy for Triple-Negative Breast Cancer
Cryoablation for Large Breast Tumors: An Alternative to Surgery for Some Patients?
SSO 2024: Nodal Isolated Tumor Cells and Axillary Dissection in Breast Cancer
Study Identifies Novel Therapeutic Targets for Males With Breast Cancer
Are Unmet Social Needs Linked to the Use of Breast Cancer Screening Mammography?
Australian Study Investigates Who May Safely Omit Postoperative Radiotherapy for Early Breast Cancer
Long-Term Update on Role of Adjuvant Abemaciclib Plus Endocrine Therapy for Early Breast Cancer
Not All Triple-Negative Breast Cancers Are Created Equal: Focus on Subtyping-Based Therapy
Novel Androgen Receptor Modulator, Enobosarm, Enters Breast Cancer Treatment Arena
Simulation Models Show Breast Cancer Screening and Treatment Advances Are Saving Lives
A Single-Port Robotic System for Nipple-Sparing Mastectomy
Final Overall Survival Analysis From PALOMA-2: Palbociclib Plus Letrozole in Advanced Breast Cancer
21-Gene Score in Ethnically Diverse, ER-Positive Breast Cancer: Implications for Young Non-Hispanic Black Women
Interrupting Breast Cancer Therapy to Attempt Pregnancy: Use of Assisted Reproductive Technologies
How Common Is Alpelisib-Induced Hyperglycemia in Metastatic Breast Cancer?
Potential Mechanism of Resistance in Breast Cancer Treatment: Focus on the PI3KA Pathway
Axillary Dissection of Residual Tumor Cells After Neoadjuvant Chemotherapy
MONARCH 3: Final Overall Survival Results With Abemaciclib-Based Therapy for Advanced Breast Cancer
Triple-Negative Breast Cancer: Are All PD-L1 Assays Created Equal?
Adding Ribociclib to Standard Hormone Therapy in Early-Stage Breast Cancer: NATALEE Update
Does Completion Axillary Lymph Node Dissection Impact Outcomes in Node-Positive Breast Cancer?
Adjuvant Atezolizumab Plus Standard Chemotherapy in Triple-Negative Breast Cancer
Regional Nodal Irradiation May Be Unnecessary for Some Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy
Can Younger Postmenopausal Patients Avoid Radiotherapy After Breast-Conserving Surgery?
SABCS 2023: Impact of Bilateral Mastectomy on Survival Among Patients With BRCA1-Mutated Breast Cancer
Long-Term Update on Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer
SABCS 2023: TROPION-Breast 01 Update on Dato-DXd in Inoperable or Metastatic Breast Cancer
SABCS 2023: Neoadjuvant Chemotherapy Plus Lead-In vs Concurrent Nivolumab in Triple-Negative Breast Cancer
SABCS 2023: Adding Atezolizumab to Neoadjuvant Therapy for High-Risk, HER2-Positive Breast Cancer
SABCS 2023: Bispecific Antibody Plus Palbociclib and Fulvestrant in Metastatic Breast Cancer
SABCS 2023: Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage, High-Risk Breast Cancer
SABCS 2023: Patient Age, Ovarian Function Suppression, and Endocrine Response
SABCS 2023: Can Pembrolizumab Plus Olaparib Improve Survival in Advanced Triple-Negative Breast Cancer?
SABCS 2023: Combination of Two HER2-Targeted Agents in Advanced HER2-Positive Breast Cancer
Breast Cancer Care in Latin America: NCCN and SLACOM Host Regional Summit
Improving Mammography Accessibility for Patients With Disabilities
Vedotin Antibody-Drug Conjugate: Focus of First-in-Human Study in Advanced Solid Tumors
Are Younger Women in Canada Experiencing Diagnostic Delays in Breast Cancer?
Final Phase III Trial Results of Trastuzumab Duocarmazine in Metastatic Breast Cancer
Do All Subtypes of Triple-Negative Breast Cancer Respond to Atezolizumab?
AKT Inhibitor Plus Hormone Therapy Approved by the FDA for Breast Cancer
Race and Neighborhood Deprivation: Predictors of Survival in Breast Cancer?
FALCON Trial: Fulvestrant vs Anastrozole in Hormone Receptor–Positive Advanced Breast Cancer
BRCA Testing in Patients With Breast Cancer: Does Type of Insurance Matter?
Update on Use of Dato-DXd Plus Durvalumab in Triple-Negative Breast Cancer
ASCO Quality 2023: How Well Are Physicians Communicating With Women Who Have Breast Cancer?
ESMO 2023: Standardized Coaching Program May Improve Oral Treatment of Advanced Breast Cancer
ESMO 2023: KEYNOTE-522 Update on Use of Pembrolizumab in Triple-Negative Breast Cancer
ESMO 2023: Focus on Pathologic Complete Response in KEYNOTE-756 Breast Cancer Trial
ESMO 2023: Update From Phase III Trial of Atezolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
ESMO 2023: 5-Year Data From monarchE Support Abemaciclib + Endocrine Therapy
Hypofractionated Radiotherapy for Locally Advanced Breast Cancer
ESMO 2023: DESTINY-Breast04 Survival Update on T-DXd in HER2-Low Breast Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.